CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 23, 2016
Result type: Reports
Project Number: SR0487-000
Product Line: Reimbursement Review

Generic Name: Vedolizumab

Brand Name: Entyvio

Manufacturer: Takeda Canada Inc.

Therapeutic Area: Crohn's disease

Indications: Crohn’s disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 31, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions